Abstract Search

ea0099ep601 | Pituitary and Neuroendocrinology | ECE2024

Personalized dosimetry as a key for optimizing radioligand therapy (RLT) with 177Lu- or 177Lu/90Y-DOTA-TATE in patients with well-differentiated neuroendocrine tumors – an update on the initial results of the DUONEN multicenter study

Opalinska Marta , Kamiński Grzegorz , Dedecjus Marek , Kowalska Aldona , Kolodziej Maciej , Saracyn Marek , Garnuszek Piotr , Lenda-Tracz Wioletta , Gąsior-Perczak Danuta , Borkowska Anna , Januszkiewicz-Caulier Joanna , Długosińksa Joanna , Sowa Staszczak Anna , Budzyńska Anna , Kubik Agata , Kacperski Krzysztof , Chalewska Wioletta , Cegła Paulina , Hubalewska-Dydejczyk Alicja , Mikolajczak Renata

Aim/Introduction: Peptide Receptor Radionuclide Therapy (PRRT) is an effective treatment for disseminated neuroendocrine tumors (NETs) expressing somatostatin receptors. Despite many published studies, the consensus on the optimal PRRT treatment algorithm has not been reached yet. The main objective of the DUONEN multicenter, randomized, phase III study (EUDRACT No: 2020-006068-99) is the development of a dosimetry-based personalized PRRT algorithm. The second goal includes th...

0 shares

Endocrine Abstracts

Personalized dosimetry as a key for optimizing radioligand therapy (RLT) with 177Lu- or 177Lu/90Y-DOTA-TATE in patients with well-differentiated neuroendocrine tumors – an update on the initial results of the DUONEN multicenter study

BiosciAbstracts